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and adherence among patients on anti-retroviral
treatment in Kenya—a quasi-experimental study
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Dennis Ross-Degnan4, Rolf Wahlström5, Göran Tomson5 , on behalf of INRUD –IAAAbstract
Background: Achieving high rates of adherence to antiretroviral therapy (ART) in resource-poor settings comprises
serious, but different, challenges in both the first months of treatment and during the life-long maintenance phase.
We measured the impact of a health system-oriented, facility-based intervention to improve clinic attendance and
patient adherence.
Methods: This was a quasi-experimental, longitudinal, controlled intervention study using interrupted time series
analysis. The intervention consisted of (1) using a clinic appointment diary to track patient attendance and monitor
monthly performance; (2) changing the mode of asking for self-reported adherence; (3) training staff on adherence
concepts, intervention methods, and use of monitoring data; (4) conducting visits to support facility teams with the
implementation.
We conducted the study in 12 rural district hospitals (6 intervention, 6 control) in Kenya and randomly selected 1894
adult patients over 18 years of age in two cohorts: experienced patients on treatment for at least one year, and newly
treated patients initiating ART during the study. Outcome measures were: attending the clinic on or before the date of
a scheduled appointment, attending within 3 days of a scheduled appointment, reporting perfect adherence, and
experiencing a gap in medication supply of more than 14 days.
Results: Among experienced patients, the percentage attending the clinic on or before a scheduled appointment
increased in both level (average total increase immediately after intervention) (+5.7%; 95% CI = 2.1, 9.3) and trend
(increase per month) (+1.0% per month; 95% CI = 0.6, 1.5) following the intervention, as did the level and trend of
those keeping appointments within three days (+4.2%; 95% CI = 1.6, 6.7; and +0.8% per month; 95% CI = 0.6, 1.1,
respectively). The relative difference between the intervention and control groups based on the monthly difference in
visit rates increased significantly in both level (+6.5; 95% CI = 1.4, 11.6) and trend (1.0% per month; 95% CI = 0.2, 1.8)
following the intervention for experienced patients attending the clinic within 3 days of their scheduled appointments.
The decrease in the percentage of experienced patients with a medication gap greater than 14 days approached
statistical significance (−11.3%; 95% CI = −22.7, 0.1), and the change seemed to persist over 11 months after the
intervention. All facility staff used appointment-keeping data to calculate adherence and discussed outcomes regularly.
Conclusion: The appointment-tracking system and monthly performance monitoring was strengthened, and patient
attendance was improved. Scale-up to national level may be considered.
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HIV and AIDS continue to affect millions of people
globally, particularly those in sub-Saharan Africa. By
December 2010, approximately 432,000 patients in Kenya
were receiving antiretroviral therapy (ART), which was an
absolute increase of 28% over 2009 figures and repre-
sented 61% of those in need [1]. More than 80% of
patients in Kenya remain on treatment one year after
initiating ART [1,2].
Adherence rates can vary enormously between facilities
[3], and poor adherence to long-term therapies compro-
mises treatment effectiveness, making this a critical public
health issue [4]. Non-adherence to prescribed ART is
one of the strongest predictors of progression to AIDS
and death among people living with HIV [5]. It is also
associated with the development of drug-resistant viral
strains [6].
Among patients on ART, different challenges are faced,
both at the patient level and at the system level, during
the early/first months of treatment as compared to the
maintenance phase. Such challenges may include disclos-
ure, food insecurity, access to HIV Information Education
and Counselling material, and stigma. It is known that
most adherence failures occur early in the course of
treatment [7,8].
Appointment-keeping rates correlate with treatment
outcomes (i.e., weight gain and CD4 counts) [9]. Bisson
and colleagues showed that using pharmacy refills to
assess ART adherence was as accurate as CD4 counts for
detecting virological failure [10], while Paterson et al.
demonstrated that resistance to antiretrovirals decreased
with better adherence [11]. Visiting clinics early after initi-
ation of ART is an independent predictor of long-term
clinical progression in HIV-positive patients [7].
Although research has shown that adequate ART adher-
ence rates can be achieved in resource-poor settings [12],
there are concerns that adherence to ART in such settings
may decline as treatment access increases [13]. Previous
multi-country studies in Ethiopia, Kenya, Rwanda, and
Uganda have identified the need to strengthen health
systems, so that facilities can use routine data to improve
adherence and clinic attendance [3,14].
Qualitative studies in Uganda and Ethiopia identified
several factors that affect ART adherence. Survey
respondents cited lack of appointments, overcrowding,
and no effective mechanisms for community outreach to
defaulters as key systems failures associated with low
adherence [8]. In Kenya, challenges in monitoring
adherence include difficulty in tracking patients and
identifying defaulters, weak community linkages,
shortage of skilled community health workers, lack of
adherence monitoring tools, large numbers of patients,
and lack of national guidelines on adherence monitoring
[15].The objective of this intervention study was to
strengthen clinical appointment and adherence monitor-
ing systems in Kenyan health facilities and measure any
effects on the patients’ attendance and adherence to ART
using standard indicators [16].
Methods
Study design and setting
We conducted a longitudinal cohort study in a conveni-
ence sample of 12 rural health facilities situated in Central
(2 facilities), Rift Valley (4 facilities), and Eastern
(6 facilities) provinces in Kenya. The facilities were
sampled from the monitoring and evaluation database
maintained by the Kenya National AIDS & STI Control
Programme (NASCOP), and was implemented over a
one-year period. Healthcare providers at the facilities
included medical officers, clinical officers, nurse practi-
tioners, pharmacy practitioners, and records officers.
Facility sample
The inclusion criteria for sampled health facilities were
providing ART for at least one year prior to the study,
having between 100 and 500 adult patients on ART, and
being located within 200 km from Nairobi. We selected
six intervention facilities that met the criteria and an
additional six control facilities that were matched to each
intervention facility based on geographical location,
number of patients on ART, and level of care. Facilities
that offered food or other economic support to patients,
had ongoing research activities, or that had been affected
by the post-election political instability in 2007 were
excluded from the study.
Study population
The study population included patients aged 18 years or
more, who were on ART. We also collected data on the
intervention implementation process from selected staff at
each clinic. The patients selected for the study were
allocated to one of two cohorts. The reason for this
division of patients was to account for the different chal-
lenges faced by staff during the first months of treatment,
compared to during the life-long maintenance phase. The
first cohort included ART-experienced patients, who had
initiated treatment at least one year prior to the study and
who had visited the clinic at least once between 13 and
15 months prior to the baseline survey. The second
cohort included all newly treated patients recruited
month-by-month from 12 months pre-intervention and
through the post- intervention period. We analyzed only
their first 120 days of treatment.
In each facility, we aimed to sample 100 experienced
patients and as many newly treated patients as possible.
Patients had all initiated treatment at the facility in
question; those who had transferred in or who had prior
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to-child transmission programs, were excluded.
Patients initiated on antiretroviral therapy were sched-
uled for an appointment in two weeks for first review.
Thereafter, time between appointments ranged from one
month up to a maximum of three months for clinically
stable patients. Medicines were dispensed based on the
days until the next clinic visit, with the normal amount of
pills lasting between 30 to 90 days.Data collection
Trained data collectors with backgrounds in clinical
medicine, pharmacy, nursing, or social science abstracted
quantitative data from patients’ clinical and pharmacy
records. Data were collected in two waves—a baseline
survey that took place one month before the start of the
intervention, and a follow-up survey 13 months after the
start of the intervention. We developed and pretested data
collection instruments in two ART facilities prior to
beginning the study. All study tools are available on
request from the first author.
Data for the cohort of experienced and new patients
were extracted from the ART clinic register and individual
patient files. We initially sampled 120 records from theTable 1 Summary of patients’ demographic and clinical chara
Characteristics of study population Experienced cohort
(n = 1894) Intervention Control
(n = 446) (n = 352)
Female (n = 1258) 289 (64.8%) 248 (70.5%
Mean age (95% CI) 39.4 (38.3–40.5) 38 (37.1–38.9
Marital status (%)
Single 72 (16.1%) 43 (12.2%)
Divorced/Widowed 119 (26.7%) 114 (32.4%
Married 181 (40.6%) 159 (45.2%
Weight at start of follow-up—mean (95% CI)
Male 58.5 (56.7,60.3) 58.3 (56.8,59.
Female 54.8 (53.5,56.0) 55 (53.9,56.1
WHO stage at ART initiation (%)
Stage 1 14 (3.1%) 46 (13.1%)
Stage 2 61 (13.7%) 84 (23.9%)
Stage 3 278 (62.3%) 172 (48.9%
Stage 4 31 (7%) 22 (6.3%)
CD4 value at ART initiation—mean (95% CI)
CD4 value 293 (269.1,316.9) 334.3 (309.8,35
Evidence of adherence counselling prior to ART initiation
Adherence counselling 387 (86.8%) 238 (67.6%
*Missing data: marital status n = 201; WHO staging n = 180; initial CD4 n = 470; initia
NB: Figures in bold show significant differences.ART clinic register, and then selected 100 patients who
qualified for the study. We also used the ART register to
identify the newly treated cohort of patients who started
ART during the period from 12 months prior to the
baseline survey date up to 3 months before the date of
final data collection. Data on perfect adherence was
abstracted from the patient clinical record (MoH-257)
based on the patient’s self-reported, recalled perfect
adherence during the three days prior to clinic visit.Study variables
Variables extracted from the clinic and pharmacy records
are included in Table 1. The outcomes for the study
included several calculated measures of clinic attendance
and treatment adherence: 1) attending the clinic on or
before the scheduled date, 2) attending the clinic within
3 days of the scheduled appointment date, 3) reporting
perfect adherence, and 4) experiencing a gap in medica-
tion supply from the clinic of more than 14 days between
recorded visits. In order to obtain the gap in medication
supply, the records of dispensing done during each clinic
or ART pharmacy visit were reviewed, and the total daily
doses of dispensed medicines were recorded for each
patient visit.cteristics
1 Newly treated cohort 2
p-value Intervention Control p-value
(n = 520) (n = 576)
) 0.0908 337 (64.8%) 384 (66.7%) 0.5171
) 0.065 38.6 (37.7–39.5) 39.2 (38.4–40.1) 0.349
0.1157 79 (15.2%) 79 (13.7%) 0.1987
) 140 (26.9%) 186 (32.3%)
) 253 (48.7%) 268 (46.5%)
9) 0.8974 54.9 (53.5,56.3) 57.3 (56,58.5) 0.0144
) 0.796 52.3 (51.1,53.5) 52.8 (51.7,53.8) 0.5529
<0.0001 50 (9.6%) 88 (15.3%) 0.0003
146 (28.1%) 199 (34.5%)
) 247 (47.5%) 224 (38.9%)
31 (6%) 21 (3.6%)
8.8) 0.0183 169.2 (154.5,183.9) 189.4 (176.1,202.7) 0.0466
) <0.0001 457 (87.9%) 401 (69.6%) < 0.0001
l adherence counseling n = 3.
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The intervention consisted of the following four
components:
1) Implementing a clinic appointment diary system for
tracking patient attendance. The diary comprised a
12-month record of visits for each patient including
the scheduled appointment date and the exact
attendance date for each visit. The diary also
included an option for the facility to monitor
monthly appointment-keeping performance for all of
their patients on ART. The diary helped the facilities
quickly identify patients who missed appointments
and then initiate timely follow-up. Patients who
missed appointments were targeted for more
focused counselling.
2) Modifying the national routine patient monitoring
form (MoH-257) (Additional file 1). The form’s self-
reported adherence question, which is asked by
trained clinicians during each patient encounter, was
changed to read as follows: “Have you missed any
medicine in the last three days?” The answer was
used to identify patients with less than perfect
adherence. Patients reporting missed doses received
extra adherence counselling.
3) Conducting targeted training of health service
providers drawn from each intervention site. The
training curriculum included content on basic
adherence concepts adapted from the national
adherence training curriculum, introduction to
adherence intervention tools, how to extract data to
measure attendance-based indicators, and how to
analyze and use the data to inform decision-making
at the facility.
4) Visiting the facility teams to support their
implementation of the intervention. We paid
particular attention to helping the facility
calculate their monthly appointment-keeping rate
(the percentage of patients arriving on or within
three days of their appointment) and use the
information during their monthly staff meetings.
Implementation of the intervention
We phased in the intervention, beginning with the first
three facilities in March 2008 and following with the next
three facilities three months later. This timing was
intended to control for any simultaneous external inter-
ventions that could influence the study outcomes. The
control facilities were not exposed to the intervention, and
contact with them was made only at the final evaluation.
The intervention in each facility was implemented over
two months. To enhance buy-in among staff, the initial
training targeted key people, including the facility in-
charge, officer in-charge of the ART clinic, records officer,pharmacist, clinician, and nurse. The training introduced
the study tools and disseminated preliminary feedback
from the baseline survey. During the training, each
facility developed its own intervention implementation
plan adapted to their setting. We thereafter made
reinforcement visits two weeks after the initial training,
and two months after the first reinforcement visit.
Supervision visit were also scheduled three months after
the second reinforcement visit for preliminary evaluation
of the implementation process. During these visits, the
study team reviewed the documentation in the diary and
the MoH-257 form, the calculation of the appointment-
keeping indicators from the clinic attendance diary, and
the recording of self-reported adherence. The study team
worked with the comprehensive care clinic team to iden-
tify gaps and challenges in the implementation and docu-
mented the implementation process, including use of the
diary, calculation of indicators, and how indicators were
used for monitoring and improvement. The providers did
not receive any incentives other than the training and
follow-up that was part of the intervention package.
Data management and analysis
Data extracted from clinical records were entered twice
into standardized Excel worksheets, compared and
corrected, and then analyzed using Stata v. 11 (StataCorp
LP, College Station, Texas, USA). We first compared the
characteristics of the intervention and control study
groups using frequency distributions and summary statis-
tics. All study outcomes were then expressed as monthly
percentages. We used segmented regression analysis to
evaluate the effects of the intervention. The regression
models included terms to estimate the baseline trend
(slope), as well as changes in the level immediately after
intervention, and the post intervention trend (slope) of
each outcome of interest. A change in level would indicate
an immediate effect of the intervention on the outcome
indicator of interest, while a change in trend (or slope) of
the regression line would point to a longer, more sustained
response for the indicator measured. We excluded a two-
month lag period following the beginning of the interven-
tion from our models to reflect the time needed for the
intervention to take effect (i.e., the expected time until
most patients scheduled prior to the intervention would
have made a follow-up visit).
Missing data in Table 1 (Demographic characteristics)
was highest for CD4 data and WHO staging. Those
experienced patients with either missing CD4 or WHO
staging data in each study arm did not have significantly
different outcome data (change in level or change in trend,
of the outcome “Appointment keeping to within 3 days”)
compared to the rest of the experienced patients.
Recording of self reported perfect adherence was
occasionally missing in the MoH 257 form. Notably, one
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and therefore about 79% of data was missing. In evaluat-
ing this specific outcome, only the experienced patients
with at least one record of self reported perfect adherence
available were considered (328 of 353 in the intervention
facilities, and 418 of 446 in the control facilities).
During data collection, all possible attempts were made
to ensure that patients’ medicine supply data were
collected, but after cleanup and validation, data were
missing in 16.2% of patient visit records in control
facilities and 12.4% in intervention facilities. It was
however noted that pharmacy refills were being issued, in
almost all cases, in whole packs of medicines i.e. in
multiples of discrete and known numbers based on the
quantities of pills in the respective packs, related to the
number of weeks remaining until the client’s next clinical
appointment. This is commonly done so that the clients
have enough medicines to meet their needs until the next
clinic visit date. We imputed missing dispensing data
based on this assumption.Ethical considerations
The Kenyatta National Hospital Ethics and Research
Committee granted ethical approval to conduct the study.
Patient names were not recorded on any of the data
collection forms, and each patient record was assigned a
unique identifying number. Written informed consent
was sought for all interviews conducted and children were
excluded in this study.Results
Demographic characteristics
The study included 1894 patients; the experienced cohort
comprised 798 patients (67% female) with a mean age of
39.4 years for intervention sites and 38.0 years for control
sites. A significantly greater percentage of experienced
patients at the intervention sites (69%) were started on
treatment at more advanced stages of illness (World
Health Organization [WHO] stages 3–4) compared to
control sites (55%). Rates of adherence counselling prior
to initiation of ART were significantly higher in the
intervention sites (87%) compared to control sites (68%)
(Table 1).
The newly treated cohort comprised 1096 patients
(66% female), with a mean age of 38.6 years for interven-
tion sites and 39.2 years for control sites. As with
experienced patients, a significantly greater percentage
of patients in intervention sites (54%) were started on
treatment at WHO stage 3–4 compared to the control
sites (43%). Adherence counselling prior to initiation of
ART in this cohort was also significantly higher in the
intervention sites (88%) compared to control sites (70%)
(Table 1).Appointment keeping
Appointment-keeping trends for new and experienced
patients at both intervention and control facilities were
relatively steady during the pre-intervention period
(Figures 1, 2, 3).
Experienced patients had significant increases in both
the level (average total increase immediately after
intervention) (+5.7%; 95% CI = 2.1, 9.3) and trend
(increase per month after intervention) (1.0% per month;
95% CI = 0.6, 1.5) of on-time appointments (Table 2). We
observed similar changes in the rates of patients attending
the clinic within 3 days of their scheduled appointments,
with an increase in level of attendance of 4.2%
(95% CI = 1.6, 6.7), and a monthly trend increase of 0.8%
(95% CI = 0.6, 1.1). Appointment-keeping at the control
facilities did not change.
The relative difference between the intervention and con-
trol groups based on the monthly difference in visit rates
increased significantly in both level (+6.5; 95% CI = 1.4,
11.6) and trend (1.0% per month; 95% CI = 0.2, 1.8) follow-
ing the intervention for experienced patients attending the
clinic within 3 days of their scheduled appointments
(Table 2).
Among newly treated patients, there was an immediate
significant increase in percentage of patients attending
clinic on time (8.8% 95% CI = 1.2, 16.3) in the intervention
cohort, but no significant change in trend or any other
outcome variables in this patient group (Table 2).
Medicine gaps of more than 14 days
The level of experienced patients who had a gap in medi-
cation supply of more than 14 days (Figure 4) decreased
following the intervention (−11.3%; 95% CI = −22.7, 0.1),
but the decrease did not reach significance (p = 0.051),
and the trend did not change. The newly treated cohort in
the intervention sites and the control sites showed no
significant changes in medication gaps after the interven-
tion (Table 2).
Self reported recalled perfect adherence
Over 90% of patients in the intervention and control
groups recorded a self-reported perfect adherence during
both the pre- and post-intervention periods, and no
significant changes in either level or trend were found.
Uptake of the intervention
Staff from all intervention facilities used the study tools
successfully. The study team’s supportive supervision
helped to resolve challenges, such as staff members not
completely filling out the diary at the beginning of imple-
mentation. The diary was useful in determining who
turned up for appointments and for initiating timely
follow-up for clients who missed their appointments.
Those who missed appointments were contacted and
Figure 1 Percentage visits kept or attended before appointment for experienced patients.
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clinic, even if on their own volition. Providers used
the revised MoH-257 patient record card and found
the question on self-reported perfect adherence within the
previous three days easy to administer to patients at the
clinics. Clients who missed treatment doses were referred
for more adherence counselling to help them overcome
barriers to adherence and emphasize its importance.
Trained staff at the facilities calculated appointment-
keeping indicators using a monthly summary sheet
in the diary. During regular staff meetings to monitor
intervention progress, the percentages for each of the
appointment-keeping indicators were used to discuss facil-
ity performance. In addition, in some facilities that had
not been holding such routine meetings, the intervention
reinforced the practice.
Discussion
Our findings show that it was possible to strengthen the
appointment-keeping and performance-monitoring sys-
tem in ART clinics in resource-constrained settings, and
improve clinic attendance, through reviewing standardizedFigure 2 Average % of visits kept within 3 days for experienced patieappointment-keeping indicators during monthly facility
management meetings. However, we were not able to
show any improvement in adherence to treatment.
Among both experienced and newly treated patients in
intervention facilities, rates of appointment-keeping
consistently increased after the intervention compared to
controls. The experienced patients had close to a signifi-
cant decrease in medication gaps, which was sustained for
11 months after the start of the intervention. The level of
changes (4.2–8.8%) may seem small, but should be seen in
the context of the very large number of people on ART. If
similar improvements could be achieved at the national
level, between 18,000 and 38,000 patients would have a
more favourable therapeutic outcome.
Standardized appointment-keeping indicators are useful
in monitoring facility performance and promoting the use
of routine data. The introduction of the appointment diary
allowed service providers to periodically generate a list of
patients who missed appointments. Failure to come to the
facility for a scheduled visit provided an early warning that
a patient was at risk of non-adherence [17]. Performance
measurement raises awareness of existing practices and isnts.
Figure 3 Percentage visits with medication gap of more than 14 days for experienced patients.
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facility summary enabled staff to track their performance
level and motivated them to strengthen their practices.
The limited use of available data to improve facility
performance has previously been mentioned as a major
challenge for many facilities in Kenya [14].
Patients need to attend appointments consistently to
manage clinical issues related to ART and to avoid gaps in
therapy [3], and coming to the clinic regularly has been
significantly associated with optimum medication adher-
ence [19]. Patients’ failure to attend the clinic when
expected is an objective indicator that is easy to ascertain
[9]; inconsistent attendance can identify patients requiring
more focused interventions such as adherence counselling
or outreach [16]. A common measure of ensuring patient
retention in ART involves tracking patients who have
missed their appointments [20,21]. Information from the
appointment diary also enabled facilities to spread their
workload by controlling the number of patients scheduled
to visit on a given day.
The percentage of experienced patients with a gap in
medication supply of more than 14 days decreased follow-
ing the intervention, although the difference was not
statistically significant. In this setting, client visits to the
health facility are nearly always linked with an antiretro-
viral prescription refill, except when patients come early
due to illness or unexpected travel. Antiretroviral medi-
cines were generally available to patients in all facilities
that participated in our study; thus, a decrease in medica-
tion gap would be linked to improved clinic attendance.
An interruption of more than 14 days of therapy has been
associated with a 50% probability of virological rebound
among suppressed patients on a non-nucleoside reverse
transcriptase inhibitor-based therapy, which predisposes
them to developing resistance [22].
When implementing and scaling-up an innovation in a
complex health system, knowledge about contextualfactors is essential [23-25]. Therefore, in addition to the
outcome measures presented here, we conducted inter-
views with representative members of the health staff and
observed team meetings and interactions in the work
places. Interview participants reported that the interven-
tion allowed facilities to anticipate their daily workload
and detect clients’ missing appointments, which helped
them take timely action. In addition, information on indi-
vidual patient attendance helped facility staff target coun-
selling efforts and adjust the intervals of patient visits.
Based on the interviews, the most important enabling
factors appeared to be the involvement of key actors from
each facility in planning, implementing, and monitoring;
the positive attitude of health care workers; and a shift of
staff members’ roles within the clinics. Task-shifting from
health care providers to peer educators, social workers,
and volunteers helped in the effort to track treatment
defaulters, remind clients to keep appointments, counsel
patients, and link patients to community health workers,
while giving health care providers more time to imple-
ment the intervention [Unpublished data from qualitative
part of the study]. Implementation constraints included
poor coordination and weak management structures
within the facilities, high staff turnover, lack of funds to
follow-up patients who missed appointments, and staff
shortages.
In considering national scale-up of this intervention, we
would recommend: paying attention to local contexts,
incentives, and institutions; anticipating unintended con-
sequences; and developing and implementing programs
that engage key actors by using data for ongoing problem-
solving [23].
Methodological considerations
The availability of routine data on clinic attendance
and dispensed medicine enabled us to use interrupted
time series analysis to demonstrate the impact of the
Table 2 Estimated changes in appointment keeping and medication gaps resulting from the intervention among experienced and newly treated patients
Pre-intervention trend (% per month) Change in level (absolute) Change in trend (% per month)
Indicator Cohort Group Coefficient (± 95% CI) p-value Coefficient (± 95% CI) p-value Coefficient (± 95% CI) p-value
Keeping appointment or attending before appointment Exp. Intervention −0.25 (−0.54, 0.04) 0.096 5.67 (2.07, 9.28) 0.002 1.04 (0.61, 1.47) <0.001
Control 0.12 (−0.21, 0.45) 0.485 −2.78 (−7.72, 2.15) 0.268 0.64 (−0.05, 1.34) 0.071
Difference −0.52 (−1, -0.04) 0.033 9.56 (−16.07, -3.04) 0.004 0.48 (−1.29, 0.33) 0.248
New Intervention −0.14 (−0.72, 0.43) 0.622 8.75 (1.21, 16.29) 0.023 −0.44 (−1.39, 0.51) 0.365
Control 0.08 (−0.45, 0.61) 0.769 −1.8 (−9.84, 6.23) 0.660 0.85 (−0.16, 1.85) 0.100
Difference −0.72 (−1.7, 0.26) 0.147 15.39 (−26.4, -4.38) 0.006 −1.23 (−0.31, 2.76) 0.117
Keeping appointment within 3 days Exp. Intervention −0.18 (−0.38, 0.01) 0.064 4.16 (1.63, 6.69) 0.001 0.84 (0.58, 1.09) <0.001
Control 0.31 (−0.15, 0.76) 0.186 0.49 (−5.41, 6.4) 0.870 −0.12 (−0.88, 0.65) 0.765
Difference −0.71 (−1.17, -0.25) 0.003 6.46 (1.35, 11.58) 0.013 0.96 (0.16, 1.77) 0.019
New Intervention 0.23 (−0.44, 0.89) 0.503 2.68 (−5.34, 10.69) 0.513 0.02 (−1.35, 1.4) 0.973
Control 0.23 (−0.12, 0.58) 0.194 −1.13 (−9.68, 7.43) 0.796 0.11 (−0.86, 1.08) 0.823
Difference −0.27 (−0.87, 0.33) 0.374 7.85 (−17.16, 1.45) 0.098 −0.31 (−0.8, 1.42) 0.585
Medication gap more than 14 days Exp. Intervention −0.15 (−0.62, 0.32) 0.523 −11.3 (−22.72, 0.07) 0.051 0.18 (−1.09, 1.46) 0.778
Control −0.48 (−0.94, -0.02) 0.041 −0.68 (−6.03, 4.66) 0.802 0.13 (−0.62, 0.87) 0.739
Difference 0.33 (−0.37, 1.02) 0.355 −10.64 (−22.62, 1.33) 0.081 0.06 (−1.22, 1.34) 0.931
New Intervention −0.37 (−1.42, 0.67) 0.484 −8.24 (−19.13, 2.65) 0.138 0.9 (−0.52, 2.32) 0.212
Control 0.05 (−0.44, 0.54) 0.830 −3.87 (−12.43, 4.69) 0.376 0.14 (−1.15, 1.42) 0.833
Difference −0.43 (−1.75, 0.90) 0.529 −4.37 (−17.6, 8.86) 0.517 0.77 (−1.15, 2.68) 0.434
Exp. = Experienced patients, New = Newly treated patients; Figures in bold show significant differences between intervention and control group.
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Figure 4 Difference in average % of visits kept within 3 days, experienced patients.
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http://www.biomedcentral.com/1472-6963/13/242intervention. The use of time series displays has been
recognized as a robust method of identifying and visualiz-
ing patterns in complex systems [23]. Segmented regres-
sion analysis of interrupted time series data makes it
possible to assess, in statistical terms, how much an inter-
vention changed an outcome of interest immediately and
over time, instantly or with delay, transiently or long-term
, and whether factors other than the intervention could
explain the change [26]. Changes can be associated and
attributed to specific interventions at specific points. Our
study’s use of control facilities and staggered intervention
minimized the risk of external confounders.
The intervention and analysis were at the system level;
we did not investigate individual patient characteristics
and how they affect adherence. Medical records at
facilities had limited demographic data, which could have
been useful in exploring adherence at the patient level. In
addition, data on opportunistic infections were not
consistently available. Records on the quantities of medi-
cines dispensed from the pharmacy were occasionally
missing. In these instances, we imputed the quantities
using an algorithm based on observed clinic norms at
individual facilities. We could not perfectly match inter-
vention and control facilities as demonstrated by differ-
ences in baseline characteristics, a common situation in
group randomized trials with small numbers of groups.
Notably, the differences in baseline characteristics
between study and control facilities that were observed
regarding WHO Staging (mostly based on clinical staging)
and CD4 values at start of treatment indicate that the
intervention facilities had patients who appeared to be
sicker at the initiation of therapy. Future studies should
determine if sicker patients actually have poorer appoint-
ment keeping trends even when on maintenance phase
(after 6 months of therapy).
Although the number of intervention facilities was small
(n = 6), the analysis methods used are robust for the
aggregated data. However, we are unable to statisticallycompare one facility to another due to the relatively small
sample sizes at each facility. Because we sampled facilities
with between 100 and 500 patients on ART, we are not
sure if our results would apply to facilities with higher or
lower number of registered patients.
At the end of the study 272 of 446 of patients were still
in care at the intervention arm, and 304 of 352 patients in
the control arm representing an attrition rate of 39% and
14% respectively. Statistical comparison of baseline
characteristics of the subset identified as dropped out,
versus those that remained till the end of the study in the
intervention arm demonstrated that the subset that
dropped out was not systematically different from the one
that remained. Therefore, we believe that the potential
bias arising from the differential dropouts in the interven-
tion and control arms is of limited importance, although
we cannot exclude the possibility that other factors may
be responsible for the observed differences. In some of the
patients’ clinical files, dropout was cited to be due to
transfer out to other facilities, death, and loss to follow up.
However, we were unable to compute the specific contri-
bution of each reason cited, because the reason for loss to
follow-up was not specified in most of the files.
Conclusion
This study demonstrated that a facility-based interven-
tion could strengthen the appointment-tracking and
performance-monitoring system and that the use of
facility-generated indicators was feasible and built the
staff ’s capacity to help patients improve their clinic
attendance. For this approach to be scaled-up to the
national level, the local context and the complex nature
of the health system should be considered.
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